Comparison of efficacy and cost between cefoperazone-sulbactam sodium and piperacillin-tazobactam sodium in the treatment of elderly patients with severe pneumonia
Objective To investigate the clinical effects of cefoperazone-sulbactam sodium and piperacillin-tazobactam sodium in elderly patients with severe pneumonia,as well as their impact on short-term prognosis,clinical symptoms,and bacterial clearance rates.Methods According to treatment method,a total of 120 elderly patients with severe pneumonia who visited Dengfeng Songzheng Traditional Chinese Medicine Hospital from March 2019 to March 2021 were divided into a control group(60 cases)and a observation group(60 cases).After admission,both groups of patients received basic treatments such as fever reduction,cough relief,and asthma relief.The control group was treated with cefoperazone-sulbactam sodium injection in addition to the basic symptomatic treatment,while the observation group received piperacillin-tazobactam sodium injection in addition to the basic symptomatic treatment.All patients were treated continuously for 2 weeks.The clinical efficacy,disappearance time of clinical symptoms,bacterial clearance rate,and treatment cost were compared between the two groups.Results The cost of drugs in the observation group was significantly higher than that in the control group(P＜0.05).There were no statistically significant differences in clinical efficacy,disappearance time of various clinical symptom,single bacterial clearance rate,total bacterial clearance rate,as well as examination,hospitalization and total costs between the two groups(P＞0.05).Conclusion Both cefoperazone-sulbactam sodium and piperacillin-tazobactam sodium demonstrate significant therapeutic effects on elderly patients with severe pneumonia.However,the cost of piperacillin-tazobactam sodium is higher,while cefoperazone-sulbactam sodium has more economic advantages.
万方数据
维普
